

The Takeda Study

Introduction:

You may be eligible for a clinical study testing a new treatment for IgA nephropathy.

What it does:

This study drug (mezagitamab) targets a protein called CD38 on certain immune cells that contribute to IgA nephropathy.

How it works:

Mezagitamab is a monoclonal antibody that binds to CD38 and triggers immune mechanisms that lead to depletion of the CD38-expressing cells, which may help lower harmful immune complexes and protein in the urine.

What participants can expect:

- 2 study phases with 19 total visits; visits become less frequent over time
- Random assignment to study drug or placebo
- Continue current medications
- Study drug provided at no cost; compensation of \$75 per visit
- Study drug only available through participation in this trial

Important considerations:

- Some immune therapies are not allowed during the study
- Certain other medications may still be allowed – we would review your specific situation together

If you're interested in learning more, please schedule an appointment with the Research Clinical Coordinator via our website or email research@khccares.com



1-833-24RENAL
khccares.com